Log in

NASDAQ:ITRMIterum Therapeutics Earnings Date, Estimates & History

+0.04 (+2.68 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $1.53
50-Day Range
MA: $3.26
52-Week Range
Now: $1.53
Volume3.04 million shs
Average Volume1.38 million shs
Market Capitalization$22.06 million
P/E RatioN/A
Dividend YieldN/A


Iterum Therapeutics (NASDAQ:ITRM) Earnings Information

Iterum Therapeutics last issued its quarterly earnings data on May 14th, 2020. The reported ($0.90) earnings per share for the quarter, beating analysts' consensus estimates of ($1.34) by $0.44. Iterum Therapeutics has generated ($7.10) earnings per share over the last year. Iterum Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 12th, 2020 based off prior year's report dates.

Iterum Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Iterum Therapeutics (NASDAQ:ITRM) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20201($0.31)($0.31)($0.31)
Q3 20201($0.25)($0.25)($0.25)
Q4 20201($0.21)($0.21)($0.21)

Iterum Therapeutics (NASDAQ ITRM) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
11/12/2019Q3 2019($1.6070)($2.15)($2.15)$0.28 millionN/A
8/14/2019Q2 2019($1.4970)($1.9273)($1.93)$0.27 millionN/A
5/14/20193/31/2019($1.35)($1.44)($1.44)$0.04 millionN/A
3/25/2019Q4 2018($2.55)($1.19)($0.66)$0.20 million$0.24 millionN/A
11/14/2018Q3 2018($1.97)($1.24)($0.71)$0.25 millionN/A
8/14/2018Q2 2018($1.44)($2.22)($2.22)$0.19 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.